A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment
出版年份 2016 全文链接
标题
A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment
作者
关键词
-
出版物
Scientific Reports
Volume 6, Issue 1, Pages -
出版商
Springer Nature
发表日期
2016-09-21
DOI
10.1038/srep33825
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Neratinib after trastuzumab in patients with HER2-positive breast cancer – Author's reply
- (2016) Arlene Chan et al. LANCET ONCOLOGY
- Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab
- (2015) Hee Jin Lee et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab
- (2015) Hee Jin Lee et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis
- (2015) D. Hanniford et al. CLINICAL CANCER RESEARCH
- MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN
- (2014) Xingming Ye et al. BMB Reports
- Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer
- (2014) Hee Jin Lee et al. BREAST CANCER RESEARCH AND TREATMENT
- A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
- (2014) K. Kleivi Sahlberg et al. CLINICAL CANCER RESEARCH
- Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients
- (2014) Axel Muendlein et al. EUROPEAN JOURNAL OF CANCER
- MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer
- (2014) Wen-Dong Bai et al. INTERNATIONAL JOURNAL OF CANCER
- MicroRNA-7 Inhibits Multiple Oncogenic Pathways to Suppress HER2Δ16 Mediated Breast Tumorigenesis and Reverse Trastuzumab Resistance
- (2014) Felicia C. Huynh et al. PLoS One
- Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis
- (2013) Jia-Xing Zhang et al. LANCET ONCOLOGY
- Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients
- (2011) Eun-Jung Jung et al. CANCER
- Identification of New MicroRNAs in Paired Normal and Tumor Breast Tissue Suggests a Dual Role for the ERBB2/Her2 Gene
- (2011) H. Persson et al. CANCER RESEARCH
- Up-regulation ofmiR-21Mediates Resistance to Trastuzumab Therapy for Breast Cancer
- (2011) Chang Gong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now